Nuvation Bio to Report Second Quarter 2026 Financial Results and Provide Business Update on August 6, 2026

Rhea-AI Summary

Nuvation Bio (NYSE: NUVB) will host a conference call and webcast on Thursday, August 6, 2026, at 8:00 a.m. ET to discuss its second quarter 2026 financial results and provide a business update. The live and archived webcast will be available via the Investor Relations section of its website.

News Market Reaction – NUVB

-0.92%

7 alerts

-0.92% Session close to close

-2.0% Trough in 1 hr 57 min

$2.18B Market Cap

0.3x Rel. Volume

In the Jul 23 session, NUVB declined 0.92%, reflecting a mild negative market reaction. Argus tracked a trough of -2.0% from its starting point during tracking. Our momentum scanner triggered 7 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEW YORK, July 22, 2026 /PRNewswire/ -- Nuvation Bio Inc. ("Nuvation Bio") (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced it will host a conference call and webcast on Thursday, August 6, 2026, at 8:00 a.m. ET to discuss its financial results and business updates for the second quarter of 2026.

Investors and the general public are invited to listen to the live webcast and may register on the Investor Relations section of the Nuvation Bio website. To access the live conference call, participants can dial +1 833-461-5787 (U.S. toll-free) and enter access code 762246460. An archived recording will be available on Nuvation Bio's website for 90 days following the event.

About Nuvation Bio
Nuvation Bio is a global oncology company focused on tackling some of the toughest challenges in cancer treatment with the goal of developing therapies that create a profound, positive impact on patients' lives. Our diverse pipeline includes taletrectinib (IBTROZI^®), a next-generation ROS1 inhibitor; safusidenib, a brain-penetrant IDH1 inhibitor; and an innovative drug-drug conjugate (DDC) program. 

Nuvation Bio was founded in 2018 by biopharma industry veteran David Hung, M.D., who previously founded Medivation, Inc., which brought to patients one of the world's leading prostate cancer medicines. Nuvation Bio has offices in New York, San Francisco, Boston, and Shanghai. For more information, visit www.nuvationbio.com or follow the company on LinkedIn and X (@nuvationbioinc). 

Media and Investor Contacts

Nuvation Bio Investor Contact
JR DeVita
ir@nuvationbio.com

Nuvation Bio Media Contact
Kaitlyn Nealy
media@nuvationbio.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/nuvation-bio-to-report-second-quarter-2026-financial-results-and-provide-business-update-on-august-6-2026-302830730.html

SOURCE Nuvation Bio, Inc.

FAQ

When will Nuvation Bio (NUVB) report its second quarter 2026 financial results?

Nuvation Bio will discuss its second quarter 2026 financial results on August 6, 2026, at 8:00 a.m. ET. According to Nuvation Bio, the results and a broader business update will be covered during a live conference call and webcast for investors and the public.

How can investors access Nuvation Bio’s Q2 2026 earnings conference call and webcast?

Investors can access the live webcast through the Investor Relations section of Nuvation Bio’s website. According to Nuvation Bio, participants may also join the conference call by dialing +1 833-461-5787 (U.S. toll-free) and entering access code 762246460 at the event time.

What is the dial-in number and access code for Nuvation Bio’s August 6, 2026 earnings call?

Participants can join the Nuvation Bio earnings call by dialing +1 833-461-5787 (U.S. toll-free) and using access code 762246460. According to Nuvation Bio, this call on August 6, 2026, at 8:00 a.m. ET will cover Q2 2026 results and business updates.

Will a replay of Nuvation Bio’s Q2 2026 webcast be available for NUVB shareholders?

Yes. An archived recording of the Nuvation Bio Q2 2026 webcast will be available on the company’s website for 90 days. According to Nuvation Bio, investors and the public can access this replay through the Investor Relations section after the live event concludes.

What type of company is Nuvation Bio (NYSE: NUVB) and what is its focus?

Nuvation Bio is a global oncology company focused on difficult cancer treatment challenges. According to Nuvation Bio, its pipeline includes taletrectinib (IBTROZI), safusidenib, and a drug-drug conjugate program, all aimed at developing therapies with meaningful impact on patients’ lives worldwide.